Looking ahead, with breakthroughs in novel molecular designs, oral formulations, small molecule drugs, and dual-target drugs pushing the boundaries of GLP-1 drug innovation, the market is expected to continue to grow.
This multi-pronged action enhances insulin sensitivity, curbs appetite, and increases energy expenditure, setting it apart from existing mono- or dual-agonists
The peptide inside the vial matters less than the vendor behind it
Mechanisms of obesity WAT releases the adipokine leptin, which regulates food intake, energy expenditure, and sympathetic innervation, while its deficiency impairs thermogenesis and lipolysis, contributing to poor fat metabolism and severe obesity (Wang et al
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
Data availability Transcriptomic analysis of sorted human beta cells are from Gene Expression Omnibus database, accession no
